Sanofi India Ltd.

NSE: SANOFI | BSE: 500674 | ISIN: INE058A01010 | Industry: Pharmaceuticals
| Expensive Performer
6273.0000 -296.50 (-4.51%)
NSE Apr 25, 2025 15:31 PM
Volume: 28,193
 

logo
Sanofi India Ltd.
26 Feb 2019
6273.00
-4.51%
Motilal Oswal
26 February 2019 4QCY18 revenue growth was muted (~8% YoY) due to a high base, with some support from Lantus (the largest brand) and the smaller brands (ranked 26-50). Gross margin shrank by ~200bp YoY (-140bp QoQ) to 57% due to increased RM cost. EBITDA margin contracted by ~110bp YoY to 18.9% (our est. 19.8%) due to higher employee cost (+60bp YoY to 14.2% of sales), partly offset by a decline in other expenses (-180bp YoY, 23.8%). Consequently, EBITDA improved ~2% 11%/16%/17% YoY to INR27.7b/INR6.2b/INR3.8b. Growth was largely driven by volumes. Growth in Chronic segment (contributed around half of sales) exceeded that in Acute segment. SANLs secondary sales grew 12% YoY ~28% of sales).
Sanofi India Ltd. is trading above all available SMAs
More from Sanofi India Ltd.
Recommended